Business Wire

Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

Del

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC). Data were presented at The Liver Meeting® 2018 in San Francisco.

PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma (cancer of the bile ducts). Fatigue, pruritus and abdominal discomfort are common symptoms of PSC that can greatly impact patients’ quality of life. There are no approved treatments for PSC.

“Gilead is committed to applying our research expertise in liver disease to address this debilitating condition which may lead to serious liver-related complications for PSC patients,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “These latest results from our Phase 2 program of GS-9674 are a positive step forward in the search for effective therapy.”

In the Phase 2, double-blind, placebo-controlled trial, 52 non-cirrhotic patients with PSC were randomized to receive GS-9674 100 mg (n=22), GS-9674 30 mg (n=20), or placebo (n=10) orally once daily for 12 weeks. After 12 weeks of treatment, patients receiving GS-9674 100 mg demonstrated significant improvements in liver biochemistry tests, with a median reduction in serum alkaline phosphatase (ALP) of 20.5 percent vs. an increase of 3.4 percent with placebo (p=0.029), median reduction in gamma-glutamyl transferase (GGT) of 30.3 percent vs. an increase of 1.1 percent with placebo (p<0.001), median reduction in alanine aminotransferase (ALT) of 49.4 percent vs. 12.9 percent with placebo (p=0.009), and a median reduction in aspartate aminotransferase (AST) of 42.3 percent vs. 10.8 percent with placebo (p=0.019). In both groups treated with GS-9674, reduced serum levels of C4, an intermediate in the synthesis of bile acids, were observed compared with placebo (-23.2 percent in the 100 mg group, p=0.21; and -30.5 percent in the 30 mg group, p=0.024). Reductions in serum bile acids were greatest with the 100 mg dose.

GS-9674 was well tolerated and the incidence of Grade 2 or 3 pruritus was numerically lower with GS-9674 100 mg (13.6 percent) and 30 mg (20 percent) compared with placebo (40 percent). There were no elevations in serum lipids. Treatment was discontinued due to adverse events in three patients treated with GS-9674 100 mg (14 percent), including one discontinuation due to pruritus, and one patient with placebo (10 percent).

A separate analysis of health-related patient-reported outcome measures (PROs) among patients enrolled in the Phase 2 trial demonstrated significant impairment of PRO scores among PSC patients with pruritus or fatigue. In the evaluation, patients treated with GS-9674 100 mg experienced significant improvement of the Primary Biliary Cholangitis – 40 (PBC-40) Emotional score (p=0.04) compared with patients treated with placebo.

“Patients living with PSC urgently need effective and tolerable treatment options,” said Michael Trauner, MD, presenting author and Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria. “These Phase 2 results are encouraging in terms of beneficial changes in liver biochemistry, markers of bile acid homeostasis, and patient-reported outcome measures. We look forward to further determining the safety and efficacy of this investigational agent.”

GS-9674 is an investigational compound and is not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Its safety and efficacy have not been determined.

About GS-9674

GS-9674 is an investigational, selective, non-steroidal agonist of the farnesoid X receptor (FXR), a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR is the primary regulator of bile acid synthesis and plays important roles in glucose and lipid metabolism. GS-9674 is being investigated for the treatment of PSC, primary biliary cholangitis (PBC), and advanced fibrosis due to nonalcoholic steatohepatitis (NASH), a chronic and progressive liver disease characterized by fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis. GS-9674 is an investigational agent and its efficacy and safety have not been determined.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.  The company strives to transform and simplify care for people with life-threatening illnesses around the world.  Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.  For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to complete the clinical trial programs evaluating GS-9674 for the treatment of primary sclerosing cholangitis in the currently anticipated timelines, or at all. In addition, there is the possibility of unfavorable results from additional clinical trials involving GS-9674. Further, it is possible that Gilead may make a strategic decision to discontinue development of GS-9674, and as a result, GS-9674 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000

Contact information

Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Arran Attridge, 650-425-8975

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IFF-LMR Naturals Leads Industry with 90 Certified Vegan Natural Extracts15.11.2018 21:15Pressemelding

Regulatory News: IFF-LMR, a subsidiary of International Flavors & Fragrances Inc (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) announced their industry-leading position of 90 natural extracts in their portfolio certified vegan by the EVE (Expertise Vegan Europe) VEGAN standards. The certified extracts include Rose EssentialTM, Rose UltimateTM, Blackcurrant Buds Absolute, Ylang Oil Complete, Vetiver Oil Haiti, Patchouli Oil Indonesia, and Geranium Heart Oil, among many others. Bertrand de Preville, General Manager, IFF-LMR said, “Our people are passionate about creating the finest ingredients and together, we are committed to delivering premium, 100% pure and natural extracts. We believe in transparency, environmental management and sustainable development.” Mr. de Preville continued, “This certification of 90 extracts is in line with IFF-LMR’s continuous dedication to our planet, people, plants and animals.” The EVE VEGAN label was selected because it is considered one of the most rigor

Rimini Street Expands Investment and Operations in Asia-Pacific15.11.2018 20:00Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that it has expanded its operations in the Asia-Pacific region with the launch of its new subsidiary, Rimini Street New Zealand Limited, and the opening of its new office in Auckland to address the growing demand for Rimini Street’s premium, ultra-responsive support services in New Zealand. Rimini Street’s expansion was announced at a gala event held at The Northern Club in Auckland, where clients, local IT leaders and the special guest of honor, Ambassador Scott P. Brown, the U.S. Ambassador to New Zealand, were hosted by Rimini Street’s general manager for Asia-Pacific, Andrew Powell, and Rimini Street corporate senior executives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005037/en/ Rimini Street launches subsidiary

Sartorius Stedim Biotech and Lonza Modify Relationship for Supply of Cell Culture Media15.11.2018 18:15Pressemelding

Sartorius Stedim Biotech (SSB) (Paris:DIM), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others. Under agreements signed today, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs. “We have a long-standing and productive partnership

Intertops Poker Launches its 20 Event Strong SOFT Series for its Recreational Player Base15.11.2018 17:46Pressemelding

Intertops Poker has launched a new tournament series aimed and created for its recreational and casual player base, with impressive prizes up for grabs. The Intertops Poker SOFT Series is spread across 20 events and offers a combined prize pool of $24,850, including a $4,100 World Series of Poker Caribbean prize package. The series starts on 19th November and will conclude on 25th November. It is available to players from all countries and markets wanting to test their skills and have fun at the tables. There are a wide range of buy-ins to suit all budgets, and the tournament kicks-off with two $500 freerolls before the series gets underway proper on 20th November. Each SOFT Series event winner will receive an Intertops Poker Soft Series Champion hoodie and a seat at the table for the Champions Tournament. The highlight of the series, the Champions Tournament takes place on 25th November at 6:30pm ET and has a guaranteed World Series of Poker Caribbean prize worth $4,100. The World Ser

Telstra: Capital Planning & Delivery Named PMO of the Year15.11.2018 17:21Pressemelding

Today, Project Management Institute (PMI), the world’s leading association for the project, program and portfolio management profession, announced that Telstra: Capital Planning & Delivery (Melbourne, Australia) has been awarded the 2018 PMO of the Year Award. In 2012, Telstra created the Capital Planning and Delivery (CP&D) function as a dedicated capability within the Finance and Strategy organization. Their purpose was clear – support the annual capital investment allocation, prioritization, and planning processes to better support investment programs and projects. Since that time, it has created a single enterprise wide investment gating model, created a sponsorship engagement model going from 0% of sponsors engaged at the start to 77% today, and enabled a culture of never stopping projects to one that stops non-viable efforts. With many other accomplishments, the core was a cultural transformation. Engagement of sponsors, enabling project management development opportunities and c

Acuris Risk Intelligence and FinScan® Announce Global Strategic Partnership15.11.2018 16:12Pressemelding

Acuris Risk Intelligence, an independent provider of data intelligence for Anti-Money Laundering (AML), Anti-Corruption and Cyber Security; and FinScan, a global leader in AML compliance solutions, have joined forces to deliver an integrated platform for seamless and efficient watch list screening and customer due diligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005681/en/ FinScan provides advanced sanctions, Politically Exposed Persons (PEP) and adverse media screening solutions for organisations worldwide. Its intelligent matching technology drastically reduces false positives and the risk of missing true hits. By combining FinScan’s accuracy and scalability with Acuris Risk Intelligence’s specialised knowledge, the partnership enables clients to screen customers and vendors against any high-risk or sanction lists using the deployment method of their choice. Joel Lange, managing director at Acuris Risk Intel